References: 1. Harvey HA, Cream LR. Biology of bone metastases: causes and consequences. Clin Breast Cancer. 2007;7(suppl 1):S7-S13. 2. Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer. 2003;98:962-969. 3. Kinnane N. Burden of bone disease. Eur J Oncol Nurs. 2007;11(suppl):S28-S31. 4. Sutent Summary of Product Characteristics. Sandwich, UK: Pfizer Ltd; 2006. 5. Saad F, Lipton A. Zoledronic acid is effective in preventing and delaying skeletal events in patients with bone metastases secondary to genitourinary cancers. BJU International. 2005;96:964-969. 6. Roodman GD. Mechanisms of bone metastasis. N Engl J Med. 2004;350:1655-1664. 7. Lipton A. Future treatment of bone metastases. Clin Cancer Res. 2006;12(suppl 20):6305s-6308s. 8. Keller ET, Dai J, Escara-Wilke J, et al. New trends in the treatment of bone metastasis. J Cell Biochem. 2007;102:1095-1102. 9. Green JR. Bisphosphonates: preclinical review. Oncologist. 2004;9(suppl 4):3-13. 10. Schran H, Ravera C, Skerjanec A, Boisclair M. Regular dosing of zoledronic acid maintains continuous suppression of osteolysis in patients with malignant bone disease. Presented at: International Bone & Mineral Society Davos Workshops; March 9-14, 2008; Davos, Switzerland. Abstract 199. 11. Kohno N, Aogi K, Minami H, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005;23:3314-3321. 12. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumours: a randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004;100:2613-2621. 13. Saad F, Gleason DM, Murray R, et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst. 2004;96:879-882. 14. Hatoum HT, Lin SJ, Smith MR, et al. Zoledronic acid and skeletal complications in patients with solid tumours and bone metastases: analysis of a National Medical claims database. Cancer. 2008;113:1438-1445.